{"description":"At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.","eventGroups":[{"deathsNumAffected":22,"deathsNumAtRisk":66,"description":"Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"EG000","otherNumAffected":60,"otherNumAtRisk":66,"seriousNumAffected":18,"seriousNumAtRisk":66,"title":"Brentuximab Vedotin"},{"deathsNumAffected":25,"deathsNumAtRisk":62,"description":"Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\\^2, tablets, orally, once daily with meals for up to 48 weeks.","id":"EG001","otherNumAffected":51,"otherNumAtRisk":62,"seriousNumAffected":18,"seriousNumAtRisk":62,"title":"Methotrexate or Bexarotene"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Peripheral sensory neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Peripheral motor neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Paraesthesia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Dysgeusia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":66},{"groupId":"EG001","numAffected":6,"numAtRisk":62}],"term":"Headache"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Dizziness"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":66},{"groupId":"EG001","numAffected":9,"numAtRisk":62}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":66},{"groupId":"EG001","numAffected":3,"numAtRisk":62}],"term":"Vomiting"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Diarrhoea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":66},{"groupId":"EG001","numAffected":5,"numAtRisk":62}],"term":"Constipation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":66},{"groupId":"EG001","numAffected":18,"numAtRisk":62}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":66},{"groupId":"EG001","numAffected":5,"numAtRisk":62}],"term":"Asthenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":66},{"groupId":"EG001","numAffected":8,"numAtRisk":62}],"term":"Pyrexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":66},{"groupId":"EG001","numAffected":6,"numAtRisk":62}],"term":"Oedema peripheral"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":66},{"groupId":"EG001","numAffected":2,"numAtRisk":62}],"term":"Chills"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Peripheral swelling"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":66},{"groupId":"EG001","numAffected":2,"numAtRisk":62}],"term":"Alopecia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":66},{"groupId":"EG001","numAffected":3,"numAtRisk":62}],"term":"Rash maculo-papular"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Urticaria"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Dry skin"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":66},{"groupId":"EG001","numAffected":2,"numAtRisk":62}],"term":"Upper respiratory tract infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":66},{"groupId":"EG001","numAffected":6,"numAtRisk":62}],"term":"Skin infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Urinary tract infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":5,"numAtRisk":62}],"term":"Staphylococcal skin infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Pain in extremity"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Arthralgia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":66},{"groupId":"EG001","numAffected":2,"numAtRisk":62}],"term":"Myalgia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":66},{"groupId":"EG001","numAffected":3,"numAtRisk":62}],"term":"Muscle spasms"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":66},{"groupId":"EG001","numAffected":3,"numAtRisk":62}],"term":"Decreased appetite"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Hyperglycaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":66},{"groupId":"EG001","numAffected":2,"numAtRisk":62}],"term":"Hyperuricaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":11,"numAtRisk":62}],"term":"Hypertriglyceridaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":66},{"groupId":"EG001","numAffected":2,"numAtRisk":62}],"term":"Weight decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":66},{"groupId":"EG001","numAffected":5,"numAtRisk":62}],"term":"Alanine aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Aspartate aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Blood cholesterol increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":5,"numAtRisk":62}],"term":"Blood triglycerides increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Dyspnoea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Cough"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":66},{"groupId":"EG001","numAffected":6,"numAtRisk":62}],"term":"Anaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Hypertension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Dry eye"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":5,"numAtRisk":62}],"term":"Cancer pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":66},{"groupId":"EG001","numAffected":6,"numAtRisk":62}],"term":"Insomnia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Anxiety"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":5,"numAtRisk":62}],"term":"Hypothyroidism"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Hypercholesterolaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":66},{"groupId":"EG001","numAffected":8,"numAtRisk":62}],"term":"Pruritus"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Pruritus generalised"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Cellulitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Superinfection bacterial"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Diverticulitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Lower respiratory tract infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"One treatment-emergent death occurred in participant with sepsis during treatment with brentuximab vedotin and is not related.","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":3,"numAtRisk":62}],"term":"Sepsis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Urosepsis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Impetigo"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Sinusitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Urinary tract infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Parotitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Periorbital infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Erysipelas"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":66},{"groupId":"EG001","numAffected":4,"numAtRisk":62}],"term":"Pyrexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Extravasation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"General physical health deterioration"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"One treatment-emergent death occurred in participant with pcALCL during treatment with brentuximab vedotin and is related.","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Multiple organ dysfunction syndrome"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Dizziness"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Neuropathy peripheral"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Neuralgia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Pancreatitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Diarrhoea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Intestinal perforation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Haemolytic uraemic syndrome"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Hepatocellular injury"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Fracture"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Hyperglycaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Hypernatraemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Musculoskeletal chest pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Neck pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Crystal arthropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"One treatment-emergent death occurred in participant with lymphoma during treatment with brentuximab vedotin and is not related.","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Lymphoma"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Squamous cell carcinoma of skin"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Stress"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Urinary retention"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Haematuria"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"One treatment-emergent death occurred in participant with pulmonary embolism during treatment with brentuximab vedotin and is not related.","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Pulmonary embolism"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Drug eruption"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Rash maculo-papular"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Dermatitis bullous"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Skin erosion"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":66},{"groupId":"EG001","numAffected":0,"numAtRisk":62}],"term":"Hypotension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Peripheral vascular disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Peripheral ischaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":66},{"groupId":"EG001","numAffected":1,"numAtRisk":62}],"term":"Skin infection"}],"timeFrame":"All-Cause mortality: Baseline up to End of study (Up to 6 years); Serious and Other adverse events: First dose of study drug through 30 days after last dose of study drug (Up to 450 days)"}